Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced th ...

On Wednesday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.09 which represents a decrease of $-0.10 or -8.40% from the prior close of $1.19. The stock opened at $1.18 ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on ITOS stock, giving a Buy rating on November 12. Daina ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.28% ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...

Other equities analysts also recently issued research reports about the company. Leerink Partnrs raised Tectonic Therapeutic to a “strong-buy” rating in a research report on Wednesday, July 24th.

HC Wainwright reissued their neutral rating on shares of Zura Bio (NASDAQ:ZURA – Free Report) in a report released on Monday ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...